Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business's stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. This represents a 9.33 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Amneal Pharmaceuticals Price Performance
NASDAQ:AMRX traded down $0.33 during trading hours on Friday, reaching $8.69. The company had a trading volume of 796,050 shares, compared to its average volume of 1,346,329. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.18 and a 1-year high of $9.48. The business's 50 day moving average price is $8.36 and its 200-day moving average price is $8.37. The firm has a market cap of $2.69 billion, a PE ratio of -12.77 and a beta of 1.05.
Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its earnings results on Friday, February 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.03). The firm had revenue of $730.52 million during the quarter, compared to analyst estimates of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same quarter in the prior year, the firm earned $0.14 earnings per share. On average, analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.
Institutional Trading of Amneal Pharmaceuticals
Several institutional investors have recently bought and sold shares of AMRX. California State Teachers Retirement System increased its stake in shares of Amneal Pharmaceuticals by 10.3% during the fourth quarter. California State Teachers Retirement System now owns 131,713 shares of the company's stock worth $1,043,000 after purchasing an additional 12,282 shares in the last quarter. Phocas Financial Corp. increased its stake in shares of Amneal Pharmaceuticals by 31.1% in the 4th quarter. Phocas Financial Corp. now owns 1,330,413 shares of the company's stock worth $10,537,000 after acquiring an additional 315,223 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth $52,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Amneal Pharmaceuticals by 45.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 318,420 shares of the company's stock valued at $2,522,000 after acquiring an additional 99,866 shares during the last quarter. Finally, Squarepoint Ops LLC grew its holdings in shares of Amneal Pharmaceuticals by 540.5% in the fourth quarter. Squarepoint Ops LLC now owns 124,744 shares of the company's stock valued at $988,000 after purchasing an additional 105,268 shares during the period. 31.82% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of brokerages recently issued reports on AMRX. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Barclays raised their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, March 3rd. Finally, StockNews.com lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, December 19th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Amneal Pharmaceuticals has a consensus rating of "Buy" and an average target price of $10.80.
Get Our Latest Analysis on Amneal Pharmaceuticals
Amneal Pharmaceuticals Company Profile
(
Get Free Report)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.
Further Reading
Before you consider Amneal Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amneal Pharmaceuticals wasn't on the list.
While Amneal Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
